Sanofi SA
SNW
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
74,846
Stocks News & Analysis
stocks
Avoid these overvalued ASX shares
The two shares with the highest price to fair value in our Australian coverage.
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
Watching AI monetization, capex’s impact on margins, and guidance on Azure.
stocks
Lithium’s latest drop and what it means for ASX investors
Volatility returns to the lithium market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,995.70 | 5.50 | 0.06% |
| CAC 40 | 8,363.14 | 23.03 | 0.28% |
| DAX 40 | 25,011.35 | 164.66 | 0.66% |
| Dow JONES (US) | 52,224.64 | 385.38 | 0.74% |
| FTSE 100 | 10,585.91 | 61.15 | 0.58% |
| HKSE | 24,950.60 | 181.69 | -0.72% |
| NASDAQ | 25,837.21 | 329.13 | 1.29% |
| Nikkei 225 | 67,436.77 | 1,204.59 | 1.82% |
| NZX 50 Index | 13,691.46 | 35.43 | 0.26% |
| S&P 500 | 7,509.20 | 65.92 | 0.89% |
| S&P/ASX 200 | 8,811.20 | 4.70 | 0.05% |
| SSE Composite Index | 3,877.52 | 13.15 | 0.34% |